New Delhi:In a record time of just 36 days a non-invasive BiPAP Ventilator 'SwasthVayu' has been developed by CSIR - National Aerospace Laboratories (NAL), Bangalore, a constituent of a lab of CSIR to treat COVID-19 patients.
Dr Shekhar C Mande, DG CSIR said that CSIR NAL team has enabled a spin-off technology based on its expertise in the aerospace design domain. The system has undergone stringent biomedical tests and beta clinical trials at NAL Health Centre.
Jitendra J Jadhav, Director CSIR-NAL said the non-invasive ventilator will be ideal to treat moderate or mid-stage severe COVID-19 patients who do not require intubation and invasive ventilation.
"Based on global experience and specific inputs from pulmonologists in India and abroad, CSIR-NAL developed BIPAP non-invasive ventilator with externally connected oxygen concentrator which will be ideal to treat moderate or mid-stage severe COVID-19 patients who do not require intubation and invasive ventilation," he said.
The system has been certified for safety and performance by National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited agencies and undergone stringent biomedical tests.